Recruiting Inflammatory Bowel Disease Studies in Orlando
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately...
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this stud...
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to ved...
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with mo...
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disa...
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderat...
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease....
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis (ROSETTA)
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)...
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participa...
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, ...
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with mode...
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the saf...
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim...
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consist...
About Inflammatory Bowel Disease Clinical Trials in Orlando
Inflammatory bowel disease (IBD) encompasses chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis. It affects millions worldwide and can cause debilitating symptoms. Treatment includes anti-inflammatory drugs, immunosuppressants, biologics, and surgery.
There are currently 14 inflammatory bowel disease clinical trials recruiting participants in Orlando, FLORIDA. These studies are seeking a combined 3,070 participants. Research is being sponsored by Hoffmann-La Roche, Takeda, Eli Lilly and Company and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Inflammatory Bowel Disease Clinical Trials in Orlando — FAQ
Are there inflammatory bowel disease clinical trials in Orlando?
Yes, there are 14 inflammatory bowel disease clinical trials currently recruiting in Orlando, FLORIDA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Orlando?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orlando research site will contact you about next steps.
Are clinical trials in Orlando free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orlando studies also compensate for your time and travel.
What inflammatory bowel disease treatments are being tested?
The 14 active trials in Orlando are testing new therapies including novel drugs, biologics, and treatment approaches for inflammatory bowel disease.
Data updated March 2, 2026 from ClinicalTrials.gov